Quick Answer
Structure Therapeutics Inc. reported Net Income of -$141.20 million for fiscal year 2025.
Structure Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$141.20M -15.2% |
-$122.53M -36.7% |
-$89.62M -74.6% |
-$51.32M | — |
| Diluted EPS | -$0.80 -2.6% |
-$0.78 +3.7% |
-$0.81 +85.3% |
-$5.51 | — |
| Total Assets | $1.58B +75.3% |
$903.33M +87.4% |
$482.02M +392.6% |
$97.84M | — |
| Cash and Equivalents | $799.62M +371.7% |
$169.51M +30.6% |
$129.79M +397.5% |
$26.09M | — |
| Stockholders Equity | $1.52B +75.3% |
$864.84M +90.9% |
$452.97M +493.4% |
-$115.14M -77.9% |
-$64.73M |
| R&D Expense | $225.25M +107.0% |
$108.81M +55.2% |
$70.10M +93.7% |
$36.19M | — |
| Operating Income | -$176.56M -11.6% |
-$158.23M -54.0% |
-$102.78M -95.5% |
-$52.56M | — |
| Shares Outstanding | 212.51M +23.7% |
171.86M +23.4% |
139.22M +1222.5% |
10.53M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$65.71M | -93.4% | -6.6% |
| Diluted EPS | September 30, 2025 | -$0.37 | -85.0% | -37.0% |
| Total Assets | September 30, 2025 | $832.16M | -10.8% | +1.9% |
| Cash and Equivalents | September 30, 2025 | $102.91M | -40.2% | -30.0% |
| Stockholders Equity | September 30, 2025 | $770.02M | -14.1% | -0.3% |
| R&D Expense | September 30, 2025 | $58.99M | +81.0% | +7.8% |
| Operating Income | September 30, 2025 | -$73.79M | -61.0% | -4.7% |
| Shares Outstanding | September 30, 2025 | 182.03M | +6.0% | +5.4% |
- Structure Therapeutics Inc. reported Net Income of -$141.20 million for fiscal year 2025.
- Structure Therapeutics Inc. showed a decrease of -15.2% in Net Income compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
- Structure Therapeutics Inc. showed a decrease of -2.6% in Diluted EPS compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Total Assets of $1.58 billion for fiscal year 2025.
- Structure Therapeutics Inc. showed an increase of +75.3% in Total Assets compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Cash and Equivalents of $799.62 million for fiscal year 2025.
- Structure Therapeutics Inc. showed an increase of +371.7% in Cash and Equivalents compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Stockholders Equity of $1.52 billion for fiscal year 2025.
- Structure Therapeutics Inc. showed an increase of +75.3% in Stockholders Equity compared to the prior fiscal year.
- Structure Therapeutics Inc. reported R&D Expense of $225.25 million for fiscal year 2025.
- Structure Therapeutics Inc. showed an increase of +107.0% in R&D Expense compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Operating Income of -$176.56 million for fiscal year 2025.
- Structure Therapeutics Inc. showed a decrease of -11.6% in Operating Income compared to the prior fiscal year.
- Structure Therapeutics Inc. reported Shares Outstanding of 212.51 million shares for fiscal year 2025.
- Structure Therapeutics Inc. showed an increase of +23.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: